Search

Displaying results 5081 - 5090 of 10000 in total
  1. Drug

    Padimate A

    go.drugbank.com/drugs/DB11229
    ApprovedWithdrawn

    Padimate A is an ester derivative of PABA and an ingredient in some sunscreens. … In Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens.

    Synonyms: Padimate A
  2. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

  3. Drug

    BI-765063

    go.drugbank.com/drugs/DB17482
    Investigational

    BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).

  4. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  5. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. … The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects.

  6. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others. … Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  7. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    MAD) Phase I trials. … Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and

  8. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  9. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. … Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.

  10. Drug

    Phenoxybenzamine

    go.drugbank.com/drugs/DB00925
    ApprovedInvestigational

    An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.